Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS)

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 40, 2012, Pages 16190-16195

  Breitkopf, Susanne B ^a,b   Yuan, Min ^a   Pihan, German A ^a   Asara, John M ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Personalized medicine; Protein protein interactions; Targeted therapies

Indexed keywords

ADAPTOR PROTEIN; BCR ABL PROTEIN; BORTEZOMIB; BUPARLISIB; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTYROSINE; PROTEIN KINASE B; PROTEIN P85; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ARTICLE; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; TANDEM MASS SPECTROMETRY;

BASE SEQUENCE; CELL LINE, TUMOR; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; FUSION PROTEINS, BCR-ABL; GRB2 ADAPTOR PROTEIN; HUMANS; IMMUNOPRECIPITATION; INDIVIDUALIZED MEDICINE; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; PROTEIN-TYROSINE KINASES; PROTEOMICS; RECOMBINANT FUSION PROTEINS; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 84867060065     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1212759109     Document Type: Article

References (62)

1. Gstaiger M, Aebersold R (2009) Applying mass spectrometry-based proteomics to genetics, genomics and network biology. Nat Rev Genet 10:617-627.
2. Choudhary C, Mann M (2010) Decoding signalling networks by mass spectrometrybased proteomics. Nat Rev Mol Cell Biol 11:427-439.
3. Schreiber TB, Mäusbacher N, Breitkopf SB, Grundner-Culemann K, Daub H (2008) Quantitative phosphoproteomics - an emerging key technology in signal-transduction research. Proteomics 8:4416-4432.
4. Anderson NL, et al. (2009) A human proteome detection and quantitation project. Mol Cell Proteomics 8:883-886.
5. Yang X, et al. (2011) Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Res 71:5965-5975.
6. Jia S, et al. (2011) Relative quantification of protein-protein interactions using a dual luciferase reporter pull-down assay system. PLoS ONE 6:e26414.
7. Mosley AL, et al. (2011) Highly reproducible label free quantitative proteomic analysis of RNA polymerase complexes. Mol Cell Proteomics 10: M110 000687.
8. Wang Q, et al. (2011) Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci USA 108:2444-2449.
9. Zhang G, et al. (2011) Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res 10:305-319.
10. Gavin AC, Maeda K, Kühner S (2011) Recent advances in charting protein-protein interaction: mass spectrometry-based approaches. Curr Opin Biotechnol 22:42-49.
11. Charbonnier S, Gallego O, Gavin AC (2008) The social network of a cell: Recent advances in interactome mapping. Biotechnol Annu Rev 14:1-28. (Pubitemid 351916583)
12. Aloy P, et al. (2004) Structure-based assembly of protein complexes in yeast. Science 303:2026-2029. (Pubitemid 38393279)
13. Gavin AC, et al. (2002) Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 415:141-147.
14. Friedman AA, et al. (2011) Proteomic and functional genomic landscape of receptor tyrosine kinase and ras to extracellular signal-regulated kinase signaling. Sci Signal 4:rs10.
15. Sowa ME, Bennett EJ, Gygi SP, Harper JW (2009) Defining the human deubiquitinating enzyme interaction landscape. Cell 138:389-403.
16. Stelzl U, et al. (2005) A human protein-protein interaction network: A resource for annotating the proteome. Cell 122:957-968. (Pubitemid 41345212)
17. Zhang X, et al. (2011) Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol Cell 41:567-578.
18. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644.
19. Bisson N, et al. (2011) Selected reaction monitoring mass spectrometry reveals the dynamics of signaling through the GRB2 adaptor. Nat Biotechnol 29:653-658.
20. Cheng AM, et al. (1998) Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell 95:793-803. (Pubitemid 29014459)
21. Avruch J, et al. (2001) Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56:127-155.
22. Bergström Lind S, et al. (2011) Toward a comprehensive characterization of the phosphotyrosine proteome. Cell Signal 23:1387-1395.
23. Alonso A, et al. (2004) Protein tyrosine phosphatases in the human genome. Cell 117:699-711. (Pubitemid 38748887)
24. Takeuchi K, Ito F (2011) Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 34:1774-1780.
25. Olsen JV, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127:635-648. (Pubitemid 44647421)
26. Rush J, et al. (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23:94-101. (Pubitemid 41724631)
27. Shaughnessy JD, Jr., Barlogie B (2002) Integrating cytogenetics and gene expression profiling in themolecular analysis of multiple myeloma. Int J Hematol 76(Suppl 2):59-64.
28. Martiat P, et al. (1990) P190 BCR/ABL transcript in a case of Philadelphia-positive multiple myeloma. Leukemia 4:751-754. (Pubitemid 20385398)
29. Roper N, et al. (2010) An asymptomatic 61-year-old man with BCR-ABL-positive bone marrow following autologous transplantation for multiple myeloma. Am J Hematol 85:944-946.
30. Asara JM, Christofk HR, Freimark LM, Cantley LC (2008) A label-free quantification method by MS/MS TIC compared to SILAC and spectral counting in a proteomics screen. Proteomics 8:994-999. (Pubitemid 351441438)
31. Gazdar AF, Oie HK, Kirsch IR, Hollis GF (1986) Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 67:1542-1549. (Pubitemid 16075955)
32. Ernst TJ, Gazdar A, Ritz J, Shipp MA (1988) Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood 72:1163-1167. (Pubitemid 18265874)
33. Engelman JA, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043. (Pubitemid 46799492)
34. Guix M, et al. (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118:2609-2619. (Pubitemid 351949788)
35. Wickrema A, et al. (1999) Engagement of Gab1 and Gab2 in erythropoietin signaling. J Biol Chem 274:24469-24474.
36. Gu H, Pratt JC, Burakoff SJ, Neel BG (1998) Cloning of p97/Gab2, the major SHP2- binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol Cell 2:729-740. (Pubitemid 128378981)
37. Yonezawa K, et al. (1992) Insulin-dependent formation of a complex containing an 85-kDa subunit of phosphatidylinositol 3-kinase and tyrosine-phosphorylated insulin receptor substrate 1. J Biol Chem 267:25958-25965.
38. Aronheim A, et al. (1994) Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway. Cell 78:949-961. (Pubitemid 24292324)
39. Yu M, et al. (2006) The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J Biol Chem 281:28615-28626. (Pubitemid 44507004)
40. Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJ (1996) A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature 379:560-564. (Pubitemid 26049586)
41. Breitkopf SB, Oppermann FS, Keri G, Grammel M, Daub H (2010) Proteomics analysis of cellular imatinib targets and their candidate downstream effectors. J Proteome Res 9:6033-6043.
42. Zhang Y, et al. (2005) Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics 4:1240-1250. (Pubitemid 41448712)
43. Heibeck TH, et al. (2009) An extensive survey of tyrosine phosphorylation revealing new sites in human mammary epithelial cells. J Proteome Res 8:3852-3861.
44. Nishida K, Hirano T (2003) The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors. Cancer Sci 94:1029-1033. (Pubitemid 38035515)
45. Zhang SQ, et al. (2002) Receptor-specific regulation of phosphatidylinositol 3′-kinase activation by the protein tyrosine phosphatase Shp2. Mol Cell Biol 22:4062-4072. (Pubitemid 34556577)
46. Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M (2000) The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 20:8513-8525.
47. Lucas CM, et al. (2009) Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica 94:1362-1367.
48. Sidorova JYu, et al. (1997) A rapid RT-PCR based method for the detection of BCR-ABL translocation. Mol Pathol 50:266-268.
49. Emig M, et al. (1999) Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13:1825-1832. (Pubitemid 29535267)
50. Foroni L, et al. (2011) Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol 153:179-190.
51. Shaffer AL, et al. (2008) IRF4 addiction in multiple myeloma. Nature 454:226-231. (Pubitemid 351969894)
52. Klein U, et al. (2006) Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 7:773-782. (Pubitemid 43905877)
53. Noble ME, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303:1800-1805. (Pubitemid 38374863)
54. Dong H, et al. (2009) Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk Lymphoma 50:974-984.
55. Laubach JP, Richardson PG, Anderson KC (2010) The evolution and impact of therapy in multiple myeloma. Med Oncol 27(Suppl 1):S1-S6.
56. Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG (2007) Novel therapies in myeloma. Curr Opin Hematol 14:609-615. (Pubitemid 47494076)
57. BCC Research (2012) Kinase Inhibitors: Global Markets. Available at http://www. bccresearch.com/report/kinase-inhibitors-global-markets-bio053c. html. Accessed August 31, 2012.
58. Sawyer JR (2011) The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 204:3-12.
59. Klenn PJ, Hyun BH, Lee YH, Zheng WY (1993) Multiple myeloma and chronic myelogenous leukemia-a case report with literature review. Yonsei Med J 34:293-300.
60. Tanaka M, et al. (1998) Coexistence of chronic myelogenous leukemia and multiple myeloma. Case report and review of the literature. Acta Haematol 99:221-223. (Pubitemid 28230392)
61. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117-1134.
62. Greenman C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153-158. (Pubitemid 46398669)